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Background and the purpose of the study: The purpose of the present investigation was to characterize and
evaluate solid dispersions (SD) of indomethacin by using a novel carrier sucrose fatty acid ester (SFE 1815) to
increase its in vitro drug release and further formulating as a tablet.
Methods: Indomethacin loaded SD were prepared by solvent evaporation and melt granulation technique using
SFE 1815 as carrier in 1:0.25, 1:0.5 1:0.75 and 1:1 ratios of drug and carrier. Prepared SD and tablets were subjected
to in vitro dissolution studies in 900 mL of pH 7.2 phosphate buffer using apparatus I at 100 rpm. The promising SD
were further formulated as tablets using suitable diluent (DCL 21, Avicel PH 102 and pregelatinised starch) to attain
the drug release similar to that of SD.. The obtained dissolution data was subjected to kinetic study by fitting the
data into various model independent models like zero order, first order, Higuchi, Hixon-Crowell and Peppas
equations. Drug and excipient compatibility studies were confirmed by fourier transform infrared spectroscopy,
X-ray diffraction, differential scanning calorimetry and scanning electron microscopy.
Results: The in vitro dissolution data exhibited superior release from formulation S6 with 1:0.5 drug and carrier ratio
using solvent evaporation technique than other SDs prepared at different ratio using solvent evaporation and melt
granulation technique. The in vitro drug release was also superior to that of the physical mixtures prepared at same
ratio and also superior to SD prepared using common carriers like polyvinyl pyrollidone and PEG 4000 by solvent
evaporation technique. Tablets (T8) prepared with DCL21 as diluent exhibited superior release than the other tablets.
The tablet formulation (T8) followed first order release with Non-Fickian release.
Conclusion: SFE 1815 a novel third generation carrier can be used for the preparation of SD for the enhancement
of in vitro drug release of indomethacin an insoluble drug belonging to BCS class II.
Keywords: Solid dispersions, Indomethacin, Sucrose Fatty Acid Ester, Dissolution rateIntroduction
The therapeutic efficacy of a drug product intended to be
administered by the oral route depends upon its absorption
in the gastro-intestinal tract to end with bioavailability. It is
well established that dissolution is recurrently the rate-limit-
ing step in the gastrointestinal absorption of a drug from a
solid dosage form which belongs to BCS class II (low sol-
uble and high permeable). The drug release from poorly sol-
uble drugs has been shown to be unpredictable and still* Correspondence: sunilsonga@gmail.com
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reproduction in any medium, provided the orremains a problem to the pharmaceutical industry [1]. Sev-
eral methods that have been employed to improve the solu-
bility of poorly water soluble drugs include increasing the
particle surface area available for dissolution by milling [2],
improving the wettability with surfactants or doped crystals
[3], decreasing crystallinity by preparing a solid dispersion
[4], use of inclusion compounds such as cyclodextrin deri-
vatives [5], use of polymorphic forms or solvated com-
pounds [6] and use of salt forms. There are several
advantages and disadvantages for the above given methods.
Solid dispersions (SD) represent an ideal pharmaceutical
technique for increasing the dissolution, absorption andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of different SD using SFE 1815
Code name Method Polymer Ratio (Drug: polymer)








S9 Physical Mixing SFE 1815 1:0.5
S10 Solvent Evaporation PVP 1:0.5
S11 Solvent Evaporation PEG 4000 1:0.5
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The term “solid dispersion” refers to the dispersion of one
or more active ingredients in an inert carrier or matrix in
the solid state prepared by melting, solvent, or melting solv-
ent methods [7] which has been used by various researchers
who have reported encouraging results with different drugs
[8]. The method of preparation and the type of the carrier
used are important in influencing the properties of such
solid dispersions [9]. Among the carriers used in the forma-
tion of solid dispersions, polyethylene glycol and polyvinyl
pyrrolidone are the most commonly used. The first gener-
ation (urea) and second generation (PEG, polyvinyl
pyrrolidone, HPMC, hydroxylpropyl cellulose, starch
derivatives, cyclodextrins) of carriers have many disad-
vantages when compared to the use of third gener-
ation carriers (poloxamer, gelucire, sucrose fatty acid
esters) which are non-ionic and led to development of
superior solid dispersions.
Sucrose fatty acid esters (SFE) are nonionic surface ac-
tive agents which are mono-, di-, and tri-esters of su-
crose with fatty acids, manufactured from purified sugar
or hydrogenated edible tallow or edible vegetable oils.
These consist of sucrose residues as the hydrophilic
group or polar head and fatty acid residues as the lipo-
philic group or non-polar head with a unique emulsifica-
tion property that tolerates any temperature variation
[10,11]. SFE are currently regulated by the U.S. Food and
Drug Administration (FDA) as food additives under
chapter 21, section 172.859 of the Federal Code of Regu-
lations (CFR). However, studies of SFE in the area of
commonly used tablet formulations are limited and
emphasize using specific types of SFE for particular
approaches. These are non-toxic and biodegradable, as
they can be enzymatically hydrolyzed to sucrose and
fatty acids prior to intestinal absorption or excreted in
faeces, depending on the degree of esterfication with a
wide range of HLB values 1 – 16 [12,13].
The present investigation was focused on exploring su-
crose fatty acid ester as a drug carrier to increase the
drug solubility and the dissolution rate of indomethacin
by formation of solid dispersions using various methods.
The dissolution characteristics and physicochemical
modification of the indomethacin-SFE solid dispersions
were investigated by in vitro dissolution test, FTIR, XRD,
SEM and thermal analysis (DSC). These solid dispersions
were formulated into tablets after optimizing with suit-




Indomethacin was a gift sample from Macleods pharma-
ceuticals Ltd. India. Sucrose fatty acid ester 1815 was
obtained from Mitsubishi-Kagaku Foods Corporation,Japan. Avicel PH 102 was obtained from FMC Biopoly-
mer. DCL 21 was purchased from Zeel Pharmaceuticals,
India. All other chemicals were of reagent grade and
used as received.Methods
Composition of solid dispersions
Solid dispersions contained of 1:0.25, 1:0.5, 1:0.75 and
1:1 of indomethacin and SFE 1815 prepared by melt
granulation and solvent evaporation methods. Physical
mixtures were prepared only for the promising ratio for
comparision. Table 1 lists the solid dispersions prepared
along with the method employed for preparation, com-
position and codes.Preparation of solid dispersions
Melt granulation method
Accurately weighed amounts of carrier were placed in an
aluminum pan on a hot plate and melted, with constant
stirring, at a temperature of about 50 °C. An accurately
weighed amount of indomethacin was incorporated into
the melted carrier with stirring to ensure homogeneity.
The mixture was heated until a clear homogeneous melt
was obtained. The pan was then removed from the hot
plate and allowed to cool at room temperature and the
obtained damp mass is passed through sieve no #40. The
granules obtained were transferred to a polybag and
stored in desiccator for further studies.Solvent evaporation method
Accurately weighed amounts of indomethacin and car-
rier (SFE 1815) were dissolved in minimum quantities of
methanol in a china dish. The solution was stirred till
slurry was formed. The solvent was evaporated under
reduced pressure at 40 °C, and the resulting residue was
dried under vacuum for 3 h, stored in a desiccator at
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mesh no #40.Physical mixtures
Physical mixtures were obtained by pulverizing accur-
ately weighed amounts of drug and polymer in a glass
mortar and carefully mixed until a homogeneous mix-
ture was obtained. Drug and carrier ratio of 1:0.5 were
prepared and subsequently stored at room temperature
in desiccator.Preparation of tablets
SD powder, diluents, disintegrant and binder were
weighed as per formulae given in Table 2, these were
then passed through sieve no # 40, transferred to a poly
bag and blended for 5 min. To this homogeneous blend,
magnesium stearate presifted through # 60 was added
and blended for 2 min. The resulting blend was com-
pressed on Cadmach 16 station compression machine
under a common compression force of 2-3 Kg/cm2,
using 6 mm, round, flat faced punches.In vitro dissolution studies
Powder equivalent to indomethacin 25 mg for SD and
tablets were introduced into dissolution medium. The
dissolution medium is 900 mL of phosphate buffer pH
7.2, rotational speed of the basket was set at 100 rpm at
37 ± 0.5 °C. Aliquots (5 ml each) were withdrawn at pre-
determined time intervals by means of a syringe fitted
with a 0.45 μm pre-filter and immediately replaced with
5 mL of fresh medium maintained at 37 ± 0.5 °C. The
samples were analyzed for indomethacin using U.V.
double beam Elico SL 210 model at 318 nm. For com-
parison, dissolution studies of pure indomethacin and
INDOCAP marketed capsules along with PM and SD
prepared with polyvinyl pyrollidone (PVP) and PEG 4000
at drug and polymer ratio of 1:0.5 employing solvent
evaporation technique were also performed. All the dis-
solution experiments were carried out in triplicate. Com-
parison of dissolution profiles was done to quantify the
difference in rate and extent of drug release asTable 2 Formulae of tablets
Formulation T1 T2 T3 T4 T5 T6 T7 T8 T9
Indo+ SD 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5
Pregelatinised Starch 25 55 75
Avicel PH 102 25 55 75
DCL 21 25 55 75
Crocarmellose Sodium 3 3 3 3 3 3 3 3 3
PVP K 30 3 3 3 3 3 3 3 3 3
Magnesium Stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5influenced by the formulation and process variables in
order to find out the mode of drug release and their
kinetics.
Release kinetics
As a model-dependent approach, the dissolution data
was fitted to five popular release models such as zero-
order, first-order, Higuchi [14], Hixon-Crowel [15] and
Korsmeyer -peppas equations. The order of drug release
from matrix systems was described by using zero order
kinetics or first orders kinetics. The mechanism of drug
release from matrix systems was studied by using Higu-
chi and Hixon-Crowel equation. Model with the highest
coefficient correlation (r) was judged to be a more ap-
propriate model for the dissolution data.
According to Korsmeyer-Peppas equation, the release
exponent n value is used to characterize different release
mechanisms. If the n value is 0.5, the release mechanism
follows Fickian diffusion. If n value is >0.45 or <0.89,
the mechanism follows non-Fickian (anomalous) diffu-
sion and when n= 0.89 it will be non-Fickian case II and
if n> 0.89 it will be non-Fickian super case II transport
[16]. The equations for different models are represented
in Table 3.
Fourier transform infrared spectroscopy
FTIR spectra can be used to detect drug excipient inter-
actions by following the shift in vibrational or stretching
bands of key functional groups. FTIR spectra were
obtained by using Alpha FTIR spectrophotometer (Bru-
ker Optik GmbH, Germany). All the spectra were ana-
lyzed using OPUS 6.5 software. Samples were prepared
by KBr pellet method, which had been prepared by gen-
tly mixing 1 mg of the sample with 200 mg of KBr. The
spectra were scanned over a wave number range of 4000
- 500 cm−1.
X-ray diffraction
The physical state of indomethacin in different samples
was evaluated with X-ray powder diffraction. XRD is a
powerful tool in detecting crystallinity. The X-rayTable 3 Mathematical models for comparison of
dissolution profiles
Model Equation
Zero-order Qt ¼ Q0 þ K0





Hixon-Crowell Q1=3r  Q1=3t ¼ Kst
Korsmeyer-Peppas Qt =Q1 ¼ Kkt
n
Qt: amount of drug released in time t, Q0: initial amount of drug in the Tablet,
Qr: remaining amount of the drug in tablet, Q∞: fraction of drug released at
time t, Ko, K1, KH, Ks, KK – Rate order constants.
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eter (PW 1729, Philips, Netherlands). XRD patterns were
recorded using monochromatic Cu Kα radiation with Ni-
trogen filter at a voltage of 40 keV and a current of
40 mA. The sample was analyzed over 2θ range of 5-30°
and the data was processed with Diffrac Plus V1.01
software.
Differential scanning calorimetry
DSC is a frequently used thermo analytical technique
that generates data on melting endotherms and glass
transitions. DSC was performed utilizing Mettler DSC
821 (Mettler-Toledo, Switzerland). Samples of 3-4 mg
were encapsulated and hermetically sealed in flat bot-
tomed aluminum pan with crimped on lid. Samples were
allowed to equilibrate for 1 min and then heated in a ni-
trogen atmosphere over a temperature range from 25 °C
to 240 °C with a heating rate of 5 °C/min. An empty
aluminum pan is served as reference. Nitrogen was used
as a purge gas, at the flow rate of 20 mL/min for all the
studies. Reproducibility was checked by running the
sample in triplicate. Thermograms were obtained by the
STARe SW 9.10 software and reported.
Scanning electron microscopy
SEM has been employed to study the morphology of the
samples. The samples were mounted on the SEM sample
stab, using a double sided sticking tape and coated with
gold (200 A°) under reduced pressure (0.001 torr) for
5 min using an ion sputtering device (Jeol JFC-1100 E,
Japan). The gold coated samples were observed under
the SEM (JEOL JSM-840A, Japan) and photomicro-
graphs of suitable magnifications were obtained with the
aid of a software system (LINKISIS, Oxford, UK).
Results and discussion
In vitro dissolution studies
Solid dispersions
Gradual increase in drug release of the prepared SD was
observed with increase in concentration of the polymer
up to an extent, further increase in concentration did
not increase the drug release. Maximum drug release
was obtained at the end of 30 min for S6 by solvent evap-
oration technique using SFE 1815 polymer in 1:0.5 drug
and polymer ratio. Whereas using the same polymer but
employing melt granulation technique gave less drug re-
lease. The enhanced drug releases from SD prepared
with solvent evaporation technique in this study are in
co-relation with the previous study conducted by Patel
et al. on SD prepared using PEG 6000 and PVP using
solvent evaporation and melting methods [17]. Only
35.10%, 63.90%, 68.78% and 73.54% drug release was
observed form pure drug, S9 (PM), SD using PVP (S10)
and PEG 4000 (S11) respectively in 30 min, whereas99.77% drug was released from S6 which is shown in
Figure 1. Earlier workers also tried out to enhance the
dissolution of indomethacin by SD technique, El-Badry
et al. prepared SD using PEG4000 and Gelucire 50/13
using hot melting method, results have shown that more
amount of carrier was required and also 90 min was
required for complete release of drug [18]. The capability
to enhance or increase the drug release and bioavailabil-
ity of the insoluble drug by SFE 1815 depends upon the
common factors like excellent wettability, which could
be observed clearly from the solid dispersion since it rap-
idly left the surface and was dispersed in the bulk of the
dissolution medium which markedly increased indo-
methacin solubility and also specific features like (i) HLB
value – higher the HLB value greater is the ability to en-
hance (ii) length of fatty acid chain - shorter fatty acid
increases the release more than the longer fatty acids
[19] (iii) number of carbon atoms in the fatty acid chain
[19] (v) proportion of monoesters –higher the propor-
tion of monoesters higher is the hydrophilicity of the
surfactant [12,20,21]. The main reason for better drug
release of SD using SFE 1815 is the HLB value which is
15 and the number of monoesters (70%) in the ester
composition of the carrier. The comparative dissolution
profiles of S6 with SD prepared with other carriers, PM
prepared with same ratio as S6, pure drug and marketed
capsule are given in Figure 2.
It is well known from the literature and practical
knowledge that the SD are unstable as such, but stable
when formulated as a tablet dosage form. The best SD
(S6) prepared by solvent evaporation technique in 1:0.5
of drug: SFE1815 ratio was selected for the development
of tablets, which gave a superior and enhanced release
profile than SD prepared by melt granulation using same
carrier, SD prepared by common carriers by solvent
evaporation technique and PM.
Tablets were developed using different diluents (prege-
latinised starch, Avicel PH102 and DLC 21) in different
concentrations (25%, 55% and 75%). More than 99% of
the drug was released from all the formulations. T8 for-
mulation with 55% w/w of DCL21 gave maximum drug
release in 30 min. The initial lag in drug release when
compared with SD was due to the disintegration time
required for the tablet and the profiles are shown in
Figure 3.
Even though pregelatinised starch is more soluble than
Avicel PH102 the percent of drug released from the
tablets was less when compared to Avicel PH102. The
possible reason for that release could be the swelling na-
ture of pregelatinsed starch [22]. As the concentration of
the pregelatinized starch was increased, the percent of
drug release decreased, which is one of the reason for its
use in the development of sustained release tablets [23].
Tablets prepared with DCL 21 as diluent gave better
Figure 1 Dissolution profiles of solid dispersions with SFE 1815 as carrier, S1–S4 (melt granulation), S5–S8 (solvent evaporation).
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the more hydrophilic nature and solubility of DCL 21.
Release kinetics
The drug release of indomethacin from the formulations
T2 and T3 followed zero order kinetics which was indi-
cated by higher ‘r’ values of zero order release model. T1,
T4, T5, T6, T7, T8, and T9 followed first order release
model which was indicated by the higher ‘r’ value.Figure 2 Comparative dissolution profiles of solid dispersions S6 (SFE
pure drug and marketed capsule (Indocap).The relative contributions of drug diffusion and ero-
sion to drug release were further confirmed by subjecting
the dissolution data to Higuchi model and Hixon Cro-
well model. It was found that T2 and T3 followed zero
order kinetics with Non-Fickian diffusion mechanism.
T1, T4, T5, T7, T8 and T9 followed first order with Non-
Fickian diffusion mechanism. T6 formulation followed
first order release with erosion mechanism as the ‘r’
value obtained is greater for Hixon Crowell mechanism.1815), S9 (physical mixtures), S10 (PVP), S11 (PEG 4000) along with
Figure 3 Dissolution profiles of tablets prepared with different diluents A) T1-3 (pregelatinised starch), T4-6 (Avicel PH102) and T7-9 (DCL 21).
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release with Non-Fickian diffusion mechanism. Results
of various order plots for the tablets are shown in
Table 4.
Fourier transform infrared spectroscopy
Pure indomethacin spectra showed characteristic peaks at
3020 cm–1 (aromatic C-H stretching), 2965 cm–1 (C-H
stretching vibrations), 1761 cm–1 (C=O stretching vibra-
tions), 1261 cm–1 (asymmetric aromatic O-C stretching),
1086 cm−1 (symmetric aromatic O-H stretching).
SD (S6) and tablet formulation (T8) also exhibited the
characteristic peaks of indomethacin with no additional
peaks observed in the spectra, indicating retention of
chemical identity of indomethacin as shown in Figure 4.
However, intensity of peaks corresponding to the drug
was reduced or broadened in the SD and tabletTable 4 Kinetic models of core tablets
Model Zero Order First order Higuchi Hixon-Crowel Pepas
Batch R K0 r K r r r n
T1 0.990 1.56 0.998 0.028 0.979 0.928 0.995 0.771
T2 0.991 1.587 0.958 0.024 0.931 0.915 0.979 0.858
T3 0.982 1.687 0.944 0.023 0.893 0.888 0.986 0.881
T4 0.977 1.66 0.984 0.049 0.990 0.985 0.997 0.719
T5 0.979 2.10 0.983 0.051 0.992 0.968 0.996 0.610
T6 0.938 2.13 0.976 0.087 0.993 0.997 0.991 0.552
T7 0.937 2.07 0.982 0.072 0.994 0.993 0.984 0.532
T8 0.935 2.97 0.992 0.083 0.998 0.973 0.999 0.560
T9 0.934 3.05 0.999 0.099 0.998 0.990 0.995 0.573formulations, possibly due to the mixing with the surfac-
tant and addition of other excipients. The FTIR spectra
data confirmed that SFE 1815 did not alter the perform-
ance characteristics indicating their compatibility of the
drug.
X-ray diffraction
The X-ray diffractograms of pure drug indomethacin and
promising formulations are shown in Figure 5. The dif-
fractogram of indomethacin showed characteristic sharp
intensity diffraction peaks at 2θ values of 11.51°, 12.76°,
16.62°, 19.54°, 21.84°, 22.78°, 26.64°, 27.47° and 29.35°,
which reflected the crystalline nature of drug. Both the
formulations (S6 and T8), showed diffraction peaks at re-
spective 2θ values of pure indomethacin although their
relative intensities were reduced or there was slight shift
in their peaks, suggesting reduced degree of crystallinity
of drug in these formulations.
Differential scanning calorimetry
The DSC thermogram of pure indomethacin exhibited a
sharp endothermic peak at 164 °C corresponding to its
melting point, indicating its crystalline nature. SFE 1815
showed endothermic melting peak at 54.2 °C. There is a
shift in the melting peak of indomethacin in SD (S6) and
tablet (T8) to 158.2 °C and 158.4 °C respectively as indi-
cated in Figure 6. The shift observed in the melting peak
of indomethacin in the formulations may be due to phys-
ical interaction between the drug and excipient. Com-
pared to pure drug the melting peak was broadened to
some extent in the formulations which may be due to
changes in its crystalline form.
Figure 4 FTIR spectra of A) indomethacin, B) SFE 1815, C) S6 and D) T8.
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pure indomethacin as crystalline in nature. Surface
morphology of S6 and T8 indicated that the individ-
ual surface properties of drug were changed during
the compression process and surfactant might haveFigure 5 X-ray diffractograms of A) Indomethacin, B) SFE 1815 C) S6 abeen adsorbed on to the drug during the preparation
of SD. The appearance of the solid dispersion was
homogenous, with partial loss of drug crystallinity
and reduction in particle size, which may be reason
for faster dissolution of the drug and which was fur-
ther confirmed by DSC and XRD studies.nd D) T8.
Figure 6 DSC chromatographs of A) Indomethacin B) SFE 1815 C) S6 D) T8.
Figure 7 SEM photographs of A) Indomethacin, B) SFE1815 C) S6 D) T8.
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This study clearly shows that SD of indomethacin with
SFE 1815 employing solvent evaporation technique
improves their dissolution rates. Solvent evaporation
techniques used in the present study requires very few
quantity of organic solvent and absence of specialized
equipment. Mechanisms involved are solubilisation and
improved wetting of the drug [24] in the SFE 1815 rich
micro-environment formed at the surface of drug crys-
tals after dissolution of the polymer [25]. Solid disper-
sions formulated with SFE 1815 improved the
dissolution rate compared with physical mixtures and SD
formulated using PVP and PEG 4000 at the same con-
centrations. As SFE 1815 belongs to third generation by
virtue of their efficiency to increase the surface area and
wide range of HLB, these are more efficient than other
commonly used carriers to increase the solubility and
dissolution. There are no reports to date on the usage of
SFE 1815 as carriers. The crystallinity of the drugs was
reduced in all solid dispersions which were evident from
the XRD graphs and decreased intensity of the peaks
from DSC thermograms. The same enhanced release was
observed from the SD formulated as tablet dosage form
with DCL21 as diluent.Competing interests
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